Keith Lindor is New Editor-In-Chief of Hepatology

Article Outline

• Copyright

The new Editor-in-Chief of Hepatology is Dr Keith Lindor (Figure 2), Dean of the Mayo Medical School and Professor of Medicine in the Division of Gastroenterology and Hepatology at the Mayo Clinic College of Medicine in Rochester, Minnesota. Dr Lindor received a Bachelor’s of Chemistry from the University of Minnesota and his MD from Mayo Medical School. He was a resident in internal medicine at Bowman Grey School of Medicine of Wake Forest University. Before starting his Gastroenterology Fellowship at Mayo, he served a year in the Indian Health Service in Southern Arizona.

• 
  • View Large Image
  • Download to PowerPoint

• Keith Lindor, MD.

Dr Lindor’s interests include cholestatic liver diseases in adults, particularly primary biliary cirrhosis and primary sclerosing cholangitis, as well as nonalcoholic steatohepatitis. The focus of his research work is primarily on clinical trials and means of optimizing the medical management of patients with these disorders. He served as the Senior Associate Editor for Clinical Gastroenterology and Hepatology and also serves on the editorial board of Gastroenterology and the Journal of Clinical Gastroenterology. Having served on numerous committees for the American Association for the Study of Liver Disease (AASLD), Dr Lindor is on the Board of Directors and currently is Vice Chair for Clinical Affairs of the American Liver Foundation.

Given that Dr. Lindor views Hepatology as “an important educational arm of AASLD,” he sees several strategic goals of the organization that the journal is optimally situated to serve. “These include the promotion of basic and clinical research on liver and biliary tract disease, education of healthcare professionals, identification of public policy issues, and improving the training of professionals committed to the science and practice of hepatology.”

In addition, he points out that Hepatology “will continue to be a major source of information for new advances in the field, whether these are basic science or clinical research covering diagnoses, management of liver diseases or complications. Furthermore, “Hepatology should continue to be a forum for discussions about public policy as it relates to liver diseases, again consistent with the AASLD’s strategic plan to be active in public policy and in promoting public health. Hepatology’s reach continues to be global and it is expected that its international scope will continue to increase.”

While noting that Hepatology continues to attract numerous manuscripts, receiving roughly 1600–1800 articles per year, Dr Lindor points out that about one third of the papers would be considered clinical and two thirds basic or translational. “Our field is characterized, perhaps more than any other, by a robust interplay of basic sciences through translational research into clinical practice. A continued goal of the editors of Hepatology is to merge these 3 important components of our field into one source.”

The new Editor-in-Chief says he anticipates expanding the number of papers per issue by 15%–20%. “We will strive to provide an excellent balance between clinical and more basic mechanistic information regarding liver disease and anticipate that the extra pages will go towards publishing the increasing number of excellent clinical papers submitted to Hepatology.”